Replies to post #9428 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

Re: DIC

>The reason heparin might prevent the benefits of AT3 in DIC is that heparin is bound to the same site on AT3 that would interact with the surface receptor on the immune cell.<

Has the second part of this sentence—the part about the binding site—been conclusively established? T.i.a.